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The authors tried to differentiate malignancy-related from nonmalignant ascites 
with a sequence of sensitive followed by specific ascitic-fluid parameters. There 
were four results of this study. First, of nine parameters investigated in a first 
series of 48 patients, 28 with nonmalignant and 20 with malignancy-related ascites, 
ascitic-fluid cholesterol and fibronectin yielded the best negative predictive value of 
92% each, Carcinoembryonic antigen (CEA) and cytologic examination both showed 
a positive predictive value of 100%. Second, combining cytologic examination 
(sensitivity, 70%) and CEA determination (sensitivity, 45%) increased the sensitivity 
to 80%. Third, cytologic findings were negative in all ascitic-fluid samples with a 
cholesterol concentration below the cutoff value of 45 mg/100 ml. Fourth, based on 
the results of the first series of 48 patients, the diagnostic sequence with cholesterol 
as a sensitive parameter, followed by the combination of cytologic examination and 
CEA determination as specific parameters, was tested in a second series of 71 
patients, 37 with nonmalignant and 34 with malignancy-related ascites. Again 
cytologic examination was negative in all samples with cholesterol levels below 45 
mg/100 ml. In the total of 119 patients, this diagnostic sequence did not identify 9% 
of patients with malignancy-related ascites, and 82% of samples classified as 
malignancy related by cholesterol levels above 45 mg/100 ml were confirmed by 
positive cytologic examination and/or CEA level above 2.5 ng/ml. Thus, a 
diagnostic sequence with ascitic-fluid cholesterol determination, followed by 
cytologic examination and CEA determination, in samples with cholesterol levels 
above 45 mg/100 ml should permit a cost-efficient routine differentiation of 
malignancy-related from nonmalignant ascites. Cancer 68:1808-1814,1991. 
HE DIFFERENTIATION between malignancy-related T (MRA) and nonmalignant ascites (NMA) is impor- 
tant for further diagnostic and therapeutic procedures. 
Several components of ascitic fluid were tested for their 
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differential diagnostic usefulness. Cytologic investigation 
of ascitic fluid is specific but may produce a large per- 
centage of false-negative results; its sensitivity ranges be- 
tween 40% and 70%.'22 Therefore, other parameters of 
ascitic fluid were investigated. In addition to the most 
widely used total protein de te rmina t i~n ,~-~  several other 
parameters were considered for their usefulness in the dif- 
ferential diagnosis of ascites: ascitic-fluid lactic dehydro- 
genase (LDH)6 or carcinoembryonic antigen (CEA)'.' and 
the ratio of concentrations in ascites divided by concen- 
trations in the serum of LDH6,9,'0,' ' and p r ~ t e i n . ~ ? ~ . '  ' More 
recently, an excellent differential diagnostic efficiency was 
reported for the albumin gradient'.'' (ie., the difference 
between the concentrations of albumin in the serum and 
ascites), ascitic-fluid fibronectin," and ascitic-fluid cho- 
lesterol. ' 
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For the detection of MRA, sensitive parameters should 
be preferred over more specific ones in a first screening 
step. Confirmation of the suspected diagnosis in the 
subgroup classified as MRA by the sensitive parameter 
might then be achieved by means of a specific procedure 
in a second step. 
Therefore, we prospectively compared the differential 
diagnostic power of several ascitic-fluid parameters and 
found an efficient diagnostic sequence using a sensitive 
parameter, followed by a specific parameter. 
Materials and Methods 
The following criteria were applied for patient classi- 
fication: ( I )  NMA was identified in those patients in whom 
malignancy was excluded by ultrasonography, computed 
tomography, autopsy, or follow-up-the diagnosis of cir- 
rhosis was based mostly on histologic findings and (2) 
MRA was diagnosed where peritoneal carcinomatosis was 
found by computed tomography, peritoneoscopy, peri- 
toneal biopsy or autopsy, and follow-up-in most cases 
histologic proof of the primary tumor was obtained. In 
MRA patients liver disorders were excluded by ultraso- 
nography or computed tomography. The presence of liver 
metastases was established likewise. Subjects with neither 
cirrhotic nor malignant ascites were classified as having 
miscellaneous NMA and included in this group. 
Patients 
Two series of patients were investigated. The first series 
(48 patients) was used to compare several parameters for 
their differential diagnostic characteristics and to elaborate 
a diagnostic sequence. The second series (7 I patients) was 
used to test this diagnostic sequence. 
Series 1:  This series consisted of 28 patients ( 1  8 men 
and ten women; age range, 28 to 81 years) with NMA 
and 20 patients (six men and 14 women; age range, 18 
to 75 years) with MRA. Of the 28 patients with NMA, 
22 had cirrhosis (alcoholic in  nine, posthepatitic in four, 
biliary in two, and mixed or cryptogenic in seven patients). 
Six patients had miscellaneous NMA; two patients showed 
ovarian overstimulation from administration of gona- 
dotropic hormones for infertility, and one patient each 
had pancreatitis, peritoneal tuberculosis, Budd-Chiari 
syndrome, and systemic lupus erythematosus, respec- 
tively. Eighteen of 20 patients with MRA had peritoneal 
carcinomatosis and ovarian carcinoma (seven patients), 
carcinoma of the stomach (three patients), breast cancer 
(two patients), carcinoma ofthe bladder (one patient) and 
of the kidney (one patient), hepatocellular carcinoma (one 
patient), adenocarcinoma of unknown origin (one pa- 
tient), liposarcoma (one patient), and leukemia (one pa- 
tient), as underlying diseases. One patient with carcinoma 
of the stomach and another patient with breast cancer 
had liver metastases but no evidence of peritoneal carci- 
nomatosis. 
Series 2: The second series consisted of 71 patients. 
Thirty-seven ( 19 men and 18 women; age range, 36 to 79 
years) of these 7 1 patients had NMA. There were 30 pa- 
tients with cirrhosis of the liver and seven patients with 
miscellaneous nonmalignant diseases (four patients with 
congestive heart failure and one patient each with Budd- 
Chiari syndrome, portal vein thrombosis, and ovarian 
overstimulation). Thirty-four patients (ten men and 24 
women; age range, 27 to 83 years) in the second series 
had MRA: 32 patients had evidence of peritoneal carci- 
nomatosis with carcinoma of the ovary (14 patients), of 
the pancreas (five patients), of the breast (four patients), 
of the stomach (three patients), of the colon (three pa- 
tients), of the gallbladder (one patient), of the bladder 
(one patient), and mesothelioma (one patients) as under- 
lying diseases. Two patients had no evidence of peritoneal 
carcinomatosis: one with hepatocellular carcinoma and 
one with liposarcoma and liver metastases. 
Methods 
Samples of blood and ascites were obtained simulta- 
neously. Cytologic examination of ascitic fluid was done 
independently by two investigators on Papanicolaou and 
Giemsa stained smears of the sediment obtained by cen- 
trifugations of 10 to 20-ml samples. Total protein was 
determined by a commercially available biuret method 
(Merck, Darmstadt, Germany). Cholesterol and LDH 
were measured enzymatically with commercial test kits 
(Boehringer, Mannheim, Germany). Albumin was ana- 
lyzed by radial immunodiffusion on Nor-Partigen plates 
(Behring, Marburg, Germany). Fibronectin was deter- 
mined by means of laser nephelometry with a commercial 
antiserum against human fibronectin (Behring). The CEA 
level was determined with a monoclonal antibody by a 
commercial kit (Abbott, Wiesbaden, Germany). 
Receiver-operator characteristic curves were calculated 
by standard procedures.” Applying cutoff limits for the 
determined parameters permitted classification into four 
categories: true positive (a), true negative (b), false positive 
(c), and false negative (d). The sensitivity was calculated 
as a/(a + d) X 100, the specificity as b/(b + c) X 100, the 
positive predictive value as a/(a + c) X 100, the negative 
predictive value as b/(b + d)  X 100, and the diagnostic 
efficiency as (a + b)/(a + b + c + d) X IOO.l7 The signif- 
icance of differences of sensitivity, specificity, or efficiency 
between various parameters was evaluated by the chi- 
square test. A P value less than 0.05 was considered sta- 
tistically significant for all tests applied. 
Results 
Ascitic-fluid concentrations of the parameters investi- 
gated in the 48 patients in Series 1 are shown in Figure 
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1. This scattergram illustration shows the overlap between 
MRA and NMA was different for various parameters. 
The two patients with hepatic metastases without peri- 
toneal carcinomatosis were ranked by most parameters 
in the concentration range of NMA. 
As illustrated by the receiver-operator characteristic 
curves (Fig. 2), the differential diagnostic efficiency of 
cholesterol and fibronectin, closely followed by LDH, was 
superior to that of the other parameters. This observation 
was confirmed when sensitivity, specificity, positive and 
negative predictive values, and diagnostic efficiency were 
calculated (Table 1). At discrimination points of 45 mg/ 
100 ml and 10.0 mg/100 ml, respectively, cholesterol and 
fibronectin reached 90% sensitivity and 82% specificity. 
LDH (UA) 
FIG. I .  (Top) Albumin gradient (serum 
- ascites concentration difference of albumin) 
and ascitic fluid concentrations of cholesterol, 
fibronectin, LDH, and of (bottom) CEA, as- 
cites/serum concentration ratios of LDH (LDH 
A/S), of protein, and ascites/serum concentra- 
tion ratios of protein (protein A/S). Data ob- 
tained from 48 patients of series I :  28 patients 
with nonmalignant ascites (NMA), 22 patients 
with cirrhosis (O), six patients with miscella- 
neous nonmalignant disease (W), and from 20 
patients with malignancy-related ascites (MRA), 
18 patients with peritoneal carcinomatosis (*), 
and two patients with liver metastases (*). 
Protein determination showed 90% sensitivity at a cutoff 
value of 2.5 g/100 ml; however, the specificity was only 
68%. Specificity and differential diagnostic efficiency of 
both cholesterol and fibronectin were significantly better 
(P < 0.05) than the corresponding values of protein de- 
termination. The LDH (200 U/1) and albumin gradient 
(1.1 g/ 100 ml) yielded 85% sensitivity with 89% and 7 1 % 
specificity, respectively. 
Cytologic examination and CEA determination (2.5 ng/ 
ml) were 100% specific. The sensitivity of cytologic ex- 
amination was superior to that of CEA determination: 
70% versus 45%. A combination of these specific param- 
eters increased their sensitivity. Whereas only nine of 20 
patients with MRA were detected by CEA and 14 of 20 
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FIG. 2. Receiver-operator characteristic curves (ROC), displaying 
sensitivity and specificity at various discrimination levels for (top) cho- 
lesterol (CHO), LDH, CEA. ascites/serum concentration ratio of LDH 
(LDH A/S), and of (bottom) fibronectin (FN), protein (PRO), ascites/ 
serum concentration ratio of protein (PRO A/S), and the serum - ascites 
concentration difference of albumin (ALB). Data were obtained from 
48 patients of series I :  28 with nonmalignant and 20 with malignancy- 
related ascites. With improving differential diagnostic efficiency, the 
curves approach the left upper corner (100% sensitivity and 100% spec- 
ificity) of the illustration. 
by positive cytologic findings, 16 patients had either pos- 
itive cytologic findings ,and/or CEA values above the cutoff 
level. 
The idea of using the sequence of a sensitive parameter 
and confirmation of positive findings by means of a spe- 
cific parameter was tested in the 48 patients in Series 1. 
A sequence was examined with fibronectin or cholesterol 
(the parameters with the best negative predictive value of 
92% in Series 1) or the conventional protein determina- 
tion, as the first step, followed by a combination of cy- 
tologic examination and CEA determination for samples 
above the discrimination point. One patient with peri- 
toneal carcinomatosis and positive cytologic findings was 
misclassified by protein determination, but ascitic fluid 
with cholesterol or fibronectin concentrations below the 
respective discrimination values did not include peritoneal 
carcinomatosis samples. Two patients with MRA and liver 
metastases without peritoneal carcinomatosis showed 
cholesterol and fibronectin concentrations below the cut- 
off level. However, cytologic findings were negative in 
these patients and thus did not provide any additional 
information. All I8 patients with peritoneal carcinoma- 
tosis showed ascitic-fluid values of cholesterol, fibronectin, 
and protein above their respective cutoff levels. Sixteen 
of these samples could be confirmed as MRA by positive 
cytologic findings and/or CEA concentrations more than 
2.5 ng/ml. 
This diagnostic sequence for the differentiation of MRA 
from NMA was tested in Series 2 with 71 patients (Fig. 
3). Because cholesterol was shown to be equally effective 
to fibronectin in the first series of patients and cholesterol 
offers considerable advantages over fibronectin in terms 
of simplicity and costs of determination, it was chosen as 
the sensitive parameter to be tested in Series 2. The cho- 
lesterol concentration was compared with the total protein 
concentration; the latter is the most widely used parameter 
for ascitic-fluid differential diagnosis. There were two of 
37 patients with NMA with a cholesterol level above the 
cutoff value (one patient with congestive heart failure and 
another with portal vein thrombosis). Three of the 34 
patients with MRA had ascitic-fluid cholesterol levels less 
than 45 mg/100 ml. Cytologic examination, however, was 
negative in these three samples (one patient with perito- 
neal carcinomatosis, one with hepatocellular carcinoma, 
and one with liver metastases). Cholesterol determination 
was superior to protein determination in this second series 
of patients. Of 37 patients with NMA, 11 patients (six 
with cirrhosis and five with miscellaneous diseases) were 
classified incorrectly by protein Concentration. Of 34 pa- 
tients with MRA, seven patients (five with peritoneal car- 
cinomatosis and one each with liver metastases and he- 
patocellular carcinoma) had a total protein less than 2.5 
g/lOO ml. Three of these seven patients had positive cy- 
tologic findings in their ascitic fluid. 
After applying the sequence of cholesterol or protein 
as the initial sensitive parameter and a combination of 
cytologic findings and CEA determination as the specific 
parameter to the total number of 1 19 patients in Series 1 
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TABLE 1. Sensitivity, Specificity, Efficiency, and Positive and Negative Predictive Value of the Investigated Variables in Separating 28 Patients 
With Nonmalignant Ascites From 20 Patients With Malignancy-Related Ascites (48 Patients of Series I )  
Predictivity 
Sensitivity 
(70) 
Specificity Efficiency 
("/.) ('70) 
Positive 
(a) 
Cholesterol 
Fibronectin 
Protein 
LDH 
Albumin gradient 
Protein A/S 
LDH A/S 
90 
90 
90 
85 
85 
80 
70 
70 
45 
82 85 
82 85 
68 77 
89 88 
71 77 
79 79 
86 79 
100 88 
100 77 
78 
78 
67 
85 
68 
73 
78 
100 
100 
Negative 
('70) 
92 
92 
90 
89 
87 
85 
80 
82 
72 
Cutoff value 
45 mg/ 100 ml 
10 mg/100 ml 
2.5 g/100 ml 
200 u/1 
1.1 g/lOO ml 
0.5 
0.6 
2.5 ng/ml 
LDH: lactic dehydrogenase; CEA: carcinoembryonic antigen. 
and 2, six patients with peritoneal carcinomatosis were 
classified incorrectly by protein, four of whom would have 
been detected by positive cytologic findings. Cholesterol 
determination, however (Fig. 4), missed only one patient 
with peritoneal carcinomatosis, but cytologic findings were 
negative in this sample. With both parameters, three and 
four patients, respectively, with hepatocellular carcinoma 
or liver metastases without peritoneal involvement were 
classified incorrectly; cytologic examination was negative 
in each of these samples. Forty-nine of 50 patients with 
peritoneal carcinomatosis showed an ascitic-fluid choles- 
terol level of more than 45 mg/l00 ml, but only 44 had 
an ascitic-fluid protein level more than 2.5 g/lOO ml. The 
suspected diagnosis of MRA was confirmed by positive 
cytologic findings and/or CEA concentration more than 
2.5 ng/ml in 46 patients with elevated cholesterol and in 
42 patients with elevated protein. Thus, only ten of 119 
patients showed an ascitic-fluid cholesterol concentration 
more than 45 mg/ 100 ml but negative cytologic findings 
and CEA below cutoff level: seven patients with NMA 
and three patients with peritoneal carcinomatosis. The 
corresponding scheme with protein determination clas- 
sified 22 patients, 20 with NMA and two with peritoneal 
carcinomatosis with suspected but not confirmed MRA. 
Discussion 
Our results in patients with MRA and NMA show that 
none of the investigated ascitic-fluid parameters could 
separate these two groups of patients totally. In the first 
series of 48 patients, cholesterol, fibronectin, and protein 
were the most sensitive parameters, closely followed by 
the albumin gradient and LDH, confirming earlier 
~ t u d i e s ~ . ~ - ' ~  Each of the 18 samples of peritoneal carci- 
I 
FIG. 3. Classification of 7 1 patients 
of series 2: 37 patients with non- 
malignant ascites (30 patients with 
cirrhosis, seven patients with mis- 
cellaneous diseases) and 34 patients 
with malignancy-related ascites (32 
patients with peritoneal carcino- 
matosis, one patient with liver me- 
tastases, and one patient with he- 
patocellular carcinoma) by deter- 
mination of rather sensitive 
variables, such as cholesterol (left) or 
protein (right) in ascitic fluid. Sam- 
ples with values above the respective 
cutoff levels were classified further 
by cytology and CEA determination. 
Q: Peritoneal carcinomatosis; 0: 
cirrhosis of the liver; bd: liver metas- 
tasis-HCC; 0: miscellaneous non- 
malignant diseases. 
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FIG. 4. Classification of ithe total of I19 patients: 65 patients with 
nonmalignant ascites (52 patients with cirrhosis, 13 patients with mis- 
cellaneous diseases) and 54 patients with malignancy-related ascites (50 
patients with peritoneal carcimomatosis. four patients with liver metastases 
or hepatocellular carcinoma) by the proposed diagnostic sequence with 
cholesterol as the sensitive variable. E3: Peritoneal carcinomatosis; 0: 
cirrhosis of the liver; B: liver metastasis-HCC; 0: miscellaneous non- 
malignant diseases. 
nomatosis ascites showled cholesterol concentrations more 
than 45 mg/100 ml and fibronectin concentrations greater 
than 10 mg/100 ml whereas in one of these samples ascitic 
protein content was less than 2.5 g/100 ml. Cytologic ex- 
amination was negative in four patients with peritoneal 
carcinomatosis and also in the ascites of the two patients 
with liver metastases. Thus, additional cytologic exami- 
nation did not increase the sensitivity in ascitic samples 
with cholesterol or fibronectin concentration above the 
discrimination level. 
None of the examined parameters could classify ascites 
from patients with liver metastases without peritoneal 
carcinomatosis as MRA. This observation confirms earlier 
r e p ~ r t s l ~ , ’ ~  and could (explain the rather low sensitivities 
observed in studies witlh a considerable prevalence of such 
samples.” In a clinical setting where the underlying disease 
is to be diagnosed, however, such patients cannot be ex- 
cluded from analysis and “subgrouping” of patients,18 al- 
though useful in pathophysiologic studies, is not helpful. 
When MRA is indicated, further investigations, applying 
imaging techniques, will be preferred to define the nature 
and exact location of 1 he tumor. 
With the idea of a simple and cost-efficient diagnostic 
sequence for the differentiation of MRA and NMA in 
mind, we looked for a parameter with high negative pre- 
dictive value to exclude patients with NMA and a param- 
eter with high positive predictive value to confirm the 
suspected diagnosis of MRA in a second step. This second 
step of the diagnostic sequence was necessary to exclude 
false-positive results obtained by the sensitive parameter. 
Both fibronectin and cholesterol (each with a 92% negative 
predictability) appeared to be suitable candidates as sen- 
sitive parameters. Cholesterol determination was chosen 
for further investigation in a second series of patients be- 
cause it is available and low priced in most laboratories, 
whereas fibronectin determination can be more compli- 
cated. Protein determination, despite its rather low spec- 
ificity, was selected for comparative testing because it may 
be regarded as the most widely used routine parameter 
in ascitic fluid. 
Both cytologic examination and CEA determination 
had 100% positive predictivity. Thus, the combination of 
both parameters could increase sensitivity without reduc- 
ing specificity. In the first series of patients, the combi- 
nation of cytologic examination (70% sensitivity) and CEA 
determination (45% sensitivity) yielded 80% sensitivity at 
unchanged specificity of 100%. Thus, a combination of 
cytologic examination and CEA measurement was chosen 
as the second parameter of the differential diagnostic test 
sequence. 
In a second series of 7 1 patients, it was confirmed that 
no ascitic sample of a patient with peritoneal carcino- 
matosis and positive cytologic findings was missed by 
cholesterol determination, whereas three were missed by 
protein determination. Cytologic examination thus could 
be regarded as unnecessary in ascitic-fluid samples with 
a cholesterol level less than 45 mg/100 ml. In 30 of 31 
patients, the classification of MRA (by cholesterol deter- 
mination) was confirmed by cytologic examination and/ 
or CEA determination. Two samples misclassified as 
MRA by cholesterol were negative by cytologic findings 
and/or CEA determination. 
In the total of 1 19 patients, cholesterol had a sensitivity 
of 91% and protein, of 83%. Pursuing the idea of a se- 
quence of a sensitive and, in the case of classification as 
MRA, a specific parameter, we found in 1 19 patients that 
82% of the samples, classified as MRA by cholesterol (with 
only 66% classified by protein), were confirmed by positive 
cytologic examination and/or CEA level more than 2.5 
ng/ml. Thus all false-positive classifications were elimi- 
nated by negative cytologic examination and CEA level 
less than 2.5 ng/ml. Therefore, the following diagnostic 
sequence for an efficient differentiation of MRA and NMA 
is proposed. Ascitic-fluid cholesterol determination should 
be followed by cytologic examination and CEA deter- 
mination in samples with a cholesterol concentration 
more than 45 mg/100 ml. When proceeding according to 
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this sequence, only 8% of patients could not be classified 
correctly, namely those with ascitic cholesterol levels more 
than 45 mg/100 ml, but negative cytologic findings and 
ascitic CEA levels less than 2.5 ng/mI. Such patients, most 
of them with nonmalignant diseases, will require addi- 
tional investigations to establish the correct diagnosis. 
Furthermore it was observed that none of the investigated 
parameters was able to detect liver metastases without 
peritoneal carcinomatosis. Therefore, any clinical suspi- 
cion in this regard will have to be clarified by imaging 
techniques. However, with these limitations in mind, the 
proposed diagnostic test sequence should permit routine 
cost-effective differentiation of MRA from NMA. 
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